Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC
By Health, Drug Administration, Human Services Department, Food · Oct 8, 2026, 11:00 PM CDT
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MONOFERRIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that huma
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisNeutral languageThe statement uses formal, procedural language typical of regulatory communications, presenting facts without persuasive or emotive framing.
Legal framingThe notice frames the action as a legal requirement triggered by a patent extension filing, emphasizing compliance with statutory obligations.
Context
AI analysisMissing context
The notice does not provide the length of the regulatory review period, the criteria used to calculate it, the implications for the patent term extension, or any commentary from the drug manufacturer or other stakeholders.
Important context
Under U.S. law, a drug’s regulatory review period is used to calculate eligibility for a patent term extension, which can add up to five years to a patent’s life to compensate for time spent in FDA review.
Opinion vs. reporting
AI analysisThe text is a straightforward factual notice without editorial commentary or opinion.